MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Core Insights - Moderna has reached a settlement agreement with Genevant Sciences and Arbutus Biopharma, resolving a patent dispute related to lipid nanoparticle technology used in its COVID-19 and RSV vaccines [1][6]. Financial Implications - The settlement requires Moderna to make an upfront payment of $950 million by July 8, 2026, with an additional potential payment of up to $1.3 billion if its appeal to the Federal Circuit is unsuccessful [2][6]. - Moderna anticipates recording a charge of $950 million in Q1 2026 related to this settlement and projects to end 2026 with cash and cash equivalents between $4.5 billion and $5 billion [7]. Market Reaction - Following the announcement of the settlement, Moderna's shares rose nearly 6% in after-market trading, reflecting positive investor sentiment regarding the terms of the settlement, which are considered a small fraction of the company's vaccine sales during the pandemic [3]. Licensing Agreement - As part of the settlement, Moderna will receive a global, non-exclusive license to Genevant/Arbutus' lipid nanoparticle delivery technology and a covenant not to sue for certain patents related to Moderna's products [3][6]. Liquidity Outlook - Moderna retains access to up to $900 million under its existing credit facility, which would increase its total projected liquidity to between $5.4 billion and $5.9 billion by the end of 2026 [7]. Ongoing Legal Context - Arbutus and Genevant are also involved in a patent dispute with Pfizer and BioNTech regarding the use of lipid nanoparticle technology in their COVID-19 vaccine, Comirnaty, which is still ongoing [8].